The Economic Burden of Biological Drugs in Rheumatoid Arthritis Treatment

被引：1
|
作者：
Grega, Dominik [1 ,2 ]
Kolar, Jozef [1 ]
机构：
[1] Masaryk Univ, Fac Pharm, Dept Appl Pharm, Brno, Czech Republic
[2] Masaryk Univ, Fac Pharm, Dept Appl Pharm, Palackeho Tr 1946-1, Brno 61242, Czech Republic
来源：
VALUE IN HEALTH REGIONAL ISSUES | 2024年 / 40卷
关键词：
direct costs; elasticity factor; friction period; indirect costs; loss of productivity; FRICTION-COST METHOD; QUALITY-OF-LIFE; PRODUCTIVITY; DISABILITY; ILLNESS; IMPACT; WORK;
D O I：
10.1016/j.vhri.2023.10.001
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Objectives: This article aimed to count and compare treatment's direct (only biological drugs) and indirect (loss of productivity) costs in patients with rheumatoid arthritis from 2019 to 2021.Methods: The friction cost approach was used to establish indirect costs. Elasticity factor values and friction period for the Slovak Republic from 2019 to 2021 were determined. Direct drug costs were calculated based on average prices from 2019 to 2021 and the number of dispensed medication packages.Results: The average productivity loss reached euro2984.54 in 2019, euro3338.46 in 2020, and euro3154.01 in 2021. Total indirect costs include productivity loss and sick pay, and from 2019 to 2021 came the values of euro8.4 million, euro10.1 million, and euro8.1 million, respectively. Conclusions: Indirect costs were almost 2.5 to 3 times lower than the biological and targeted treatment costs.
引用
收藏
页码：13 / 18
页数：6
相关论文
共 50 条
  • [1] COSTS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGICAL DRUGS
    Rasmussen, C.
    Knudsen, M. S.
    Hansen, B. B.
    Lindkvist, R. M.
    VALUE IN HEALTH, 2008, 11 (06) : A541 - A541
  • [2] The economic burden of rheumatoid arthritis
    Leeb, BF
    Dunky, A
    Bröll, H
    Herrmann, J
    Herold, M
    Knoflach, P
    Pilz, I
    Siegmeth, W
    Geissler, D
    Stuby, U
    Smolen, J
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 180 - 180
  • [3] The economic burden of rheumatoid arthritis in Colombia
    Pineda-Tamayo, R
    Hincapie, ME
    Anaya, JM
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S234 - S234
  • [4] Utilization of biological drugs for the treatment of rheumatoid arthritis in Tuscany, Italy
    Roberto, Giuseppe
    Bardelli, Filippo
    Bartolini, Claudia
    Gini, Rosa
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 276 - 277
  • [5] Synthesis and Biological Activities of Chemical Drugs for the Treatment of Rheumatoid Arthritis
    Shiyang Zhou
    Huiying Zou
    Guangying Chen
    Gangliang Huang
    Topics in Current Chemistry, 2019, 377
  • [6] Advances in non-biological drugs for the treatment of rheumatoid arthritis
    Venetsanopoulou, Aliki I.
    Voulgari, Paraskevi V.
    Drosos, Alexandros A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (01) : 45 - 53
  • [7] Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian health
    Mega, Tacila Pires
    da Silva, Rondineli Mendes
    REVISTA DE SAUDE PUBLICA, 2023, 57
  • [8] Synthesis and Biological Activities of Chemical Drugs for the Treatment of Rheumatoid Arthritis
    Zhou, Shiyang
    Zou, Huiying
    Chen, Guangying
    Huang, Gangliang
    TOPICS IN CURRENT CHEMISTRY, 2019, 377 (05)
  • [9] MEDICINE TREATMENT COST OF RHEUMATOID ARTHRITIS BEFORE AND AFTER TREATMENT WITH BIOLOGICAL DRUGS
    Roux, I
    Lubbe, M.
    Burger, J. R.
    Lamprecht, J.
    VALUE IN HEALTH, 2010, 13 (07) : A307 - A308
  • [10] Economic burden of rheumatoid arthritis: a systematic review
    Cooper, NJ
    RHEUMATOLOGY, 2000, 39 (01) : 28 - 33
12345